EUVIMEDOpdag EUVIMED
Übersichtsarbeit

High Economic Burden Yet Low Clinical Value: Why Is so Much Sucralfate Prescribed?

Neha Wadhavkar iD, Laura Varnum, Steven F Moss

Basic & Clinical Pharmacology & Toxicology · 2025-07 · 137 (1)

DOI: 10.1111/bcpt.70070 ↗

At a glance

Übersichtsarbeit in Basic & Clinical Pharmacology & Toxicology, published online on 2025-06-13. Written by Neha Wadhavkar and 2 co-authors. Institution: Department of Internal Medicine, Brown University, Providence, Rhode Island, USA. Major MEDLINE topics: Sucralfate, Anti-Ulcer Agents, Gastrointestinal Diseases. Cited 1 times so far (Crossref); 11 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Sucralfate is a commonly prescribed medication in use for decades. Despite the availability of more effective medications for acid‐dyspeptic conditions, including proton pump inhibitors and histamine H2‐receptor antagonists, sucralfate continues to be utilized for upper gastrointestinal symptoms. We reviewed the limited evidence base supporting the approval and ongoing usage of sucralfate and performed a cost analysis using the ClinCalc database. The financial impact of sucralfate was comparable to famotidine, lansoprazole and ranitidine. We encourage further studies to accurately gauge the true clinical efficacy of sucralfate and to question its ongoing prescription until then.

Subjects

MeSH terms (MEDLINE)

SucralfateAnti-Ulcer AgentsGastrointestinal DiseasesHumansProton Pump InhibitorsHistamine H2 AntagonistsDrug CostsCost-Benefit Analysis

Author keywords

GERDclinical pharmacologyfunctional dyspepsiahealth economicspeptic ulcer disease

Substances

SucralfateAnti-Ulcer AgentsProton Pump InhibitorsHistamine H2 Antagonists

Authors and institutions

  • Department of Internal Medicine, Brown University, Providence, Rhode Island, USA.
  • UMass Memorial Specialty Pharmacy, UMass Memorial Medical Center, Worcester, Massachusetts, USA.
  • Division of Gastroenterology, Brown University, Providence, Rhode Island, USA.

ORCID profiles: Neha Wadhavkar

Cite

APA

Wadhavkar, N., Varnum, L., & Moss, S. F. (2025). High Economic Burden Yet Low Clinical Value: Why Is so Much Sucralfate Prescribed?. Basic & Clinical Pharmacology & Toxicology, 137(1). https://doi.org/10.1111/bcpt.70070

Vancouver

Wadhavkar N, Varnum L, Moss SF. High Economic Burden Yet Low Clinical Value: Why Is so Much Sucralfate Prescribed?. Basic & Clinical Pharmacology & Toxicology. 2025;137(1). doi:10.1111/bcpt.70070

BibTeX
@article{Wadhavkar2025,
  author = {Wadhavkar, Neha and Varnum, Laura and Moss, Steven F},
  title = {High Economic Burden Yet Low Clinical Value: Why Is so Much Sucralfate Prescribed?},
  journal = {Basic & Clinical Pharmacology & Toxicology},
  year = {2025},
  volume = {137},
  number = {1},
  doi = {10.1111/bcpt.70070}
}
Start for free →